
|Videos|October 7, 2017
CD101: A New Long-Acting Echinocandin
Author(s)Contagion® Editorial Staff
David Andes, MD, shares the half-life and dosing intervals for a new long-acting echinocandin.
Advertisement
David Andes, MD, professor and chief of infectious disease at the University of Wisconsin, shares the half-life and dosing intervals for a new long-acting echinocandin.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Top Infectious Disease News Stories Week of November 29 - December 5
2
Early 2025 Influenza Vaccination Trends Following Prior Season and H3N2 Start
3
ACIP Votes on Hepatitis B Vaccine Marks More Confusion, No Supportive Safety Data, and Uncertainty of Public Health Policy
4
Petition Urges EPA to Halt Antibiotic and Antifungal Pesticide Use Over Resistance Risks
5

















































































































































































































































































